Nasal In-Situ Gel: A Novel Drug Delivery System
Panchal DR, Patel UL, Bhimani BV, Daslaniya DJ, Patel GV
Over the past few decades, advances in the in situ gel technologies have spurred development in many medical and biomedical applications including controlled drug delivery. Many novel in situ gel based delivery matrices have been designed and fabricated to fulfill the ever increasing needs of the pharmaceutical and medical fields. In situ gelling systems are liquid at room temperature but undergo gelation when in contact with body fluids or change in pH. In situ gel forming drug delivery is a type of mucoadhesive drug delivery system. The formation of gel depends on factors like temperature modulation, pH change, presence of ions and ultraviolet irradiation from which the drug gets released in a sustained and controlled manner. Nasal delivery is a promising drug delivery option where common drug administrations such as intravenous, intramuscular or oral are inapplicable. Recently, it has been shown that many drugs have better bioavailability by nasal route than the oral route. This has been attributed to rich vasculature and a highly permeable structure of the nasal mucosa coupled with avoidance of hepatic first-pass elimination, gut wall metabolism and/or destruction in the gastrointestinal tract. The physiology of the nose presents obstacles but offers a promising route for non-invasive systemic delivery of numerous therapies and debatably drug delivery route to the brain. Thus this review focuses on nasal drug delivery, various aspects of nasal anatomy and physiology, nasal drug absorption mechanisms, various nasal drug delivery systems and their applications in drug delivery.
Nasal In Situ Gel, Absorption Enhancer, Nasal Formulation, Mucoadhesive Drug Delivery System, Microsphere Based Drug Delivery System.
Cite This Article
Panchal DR, Patel UL, Bhimani BV, Daslaniya DJ, Patel GV, Nasal In-Situ Gel: A Novel Drug Delivery System, International Journal for Pharmaceutical Research Scholars, 2012, 1(2), 457-473.